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ABSTRACT
Giardiasis, caused by an intestinal protozoan, Giardia lamblia, is a major public
health problem worldwide. Giardia infection is spread through the fecal-oral route via
contaminated water and food. It is estimated that over 280 million people are infected with
Giardia across the globe. Giardia is a non-invasive parasite and consists of a two-stage
life cycle: trophozoites and cysts. Ingested cysts undergo excystation in the proximal
small intestine, releasing two trophozoites (excyzoites). Upon reaching the distal small
intestine and colonizing there, trophozoites transform into cysts by encystation. It has
been reported earlier that the process of encystation induced the synthesis of giardial
glucosylceramide transferase-1 (gGlcT1), an enzyme of the sphingolipid pathway that
participates in various biological processes including cell division, cytokinesis, ESV
biogenesis, cyst production, and maintaining the cellular lipid homeostasis. The
modulation of its activity using molecular tools (overexpression, knockdown and rescue)
interfered with cyst production, cyst viability, and infectivity in laboratory animals. gGlcT1
is unique because it is sufficiently diverged from other eukaryotic GlcT enzymes and
consists of two active catalytic domains (CGlcT and CGalT) that catalyze the synthesis
of glucosylceramide (GlcCer) and galactosylceramide (GalCer), respectively in a noncompetitive manner.
The goal of my dissertation is to further analyze these two catalytic domains and
elucidate their roles in growth, encystation and cyst production by Giardia. To address
this goal, I used homologous recombination and overexpression techniques and created
deletion mutant Giardia cell lines. I found that both catalytic domains are active and
participate in cyst production and maintaining cyst wall structures. I also observed that
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Giardia expresses a long-chain fatty acid elongase (gFAELO) enzyme, which is involved
in the remodeling of membrane lipids by exchanging fatty acyl moieties (the Land’s cycle).
Since gFAELO is mostly expressed in cysts and gGlcT1 overexpression affects lipid
uptake, I investigated whether the interplay between gGlcT1 and gFAELO is important
for cyst production, morphology, and viability as these events dictate the parasite’s ability
to transmit the disease process. Therefore, the goal of my project was to elucidate the
molecular mechanisms behind gGlcT1 and gFAELO as they pertain to the life cycle of
Giardia. I hypothesize that The Specific Aims of the project were to: (1) use molecular
techniques to determine which domain/s of gGlcT1 were important for its function; (2) and
to investigate the how the domains of gGlcT1 and its interaction with gFAELO would
modulate cyst morphology. I hypothesize that elucidating the function of glucosylceramide
transferase will reveal the mechanisms of giardial differentiation and could be exploited
to design novel drugs against this pathogen. Therefore, The Specific Aims of the project
are to: (1) use molecular techniques to determine which domain/s of gGlcT1 were
important for its function; (2) and to investigate the how the domains of gGlcT1 and its
interaction with gFAELO would modulate cyst morphology. It is anticipated that the
findings of this study will elucidate new knowledge about gGlcT1 and gFAELO interplay
and the mechanisms of cyst production by Giardia.
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1. INTRODUCTION
1.1 Giardia and Giardiasis
Globally, diarrhea is the leading cause of human morbidity and mortality second to
lower respiratory infections (1). There are an estimated 1.5 million deaths recorded
annually, with the majority being children (2). Diarrhea is also the second most cause of
death in children worldwide (3). In a global review of diarrheal disease in children, the
most common etiological agents were found to be viral (e.g., rotavirus, calicivirus,
adenovirus), bacterial (e.g., ETEC, Shigella spp, Salmonella spp), or parasitic
pathogens (i.e., Cryptosporidium spp., Giardia lamblia, or Entamoeba histolytica) (4).
There is an established link between socioeconomic status and public health (5). A
long-standing example of this is how diarrheal illnesses play a prominent role in the
morbidity and mortality of children living in developing countries (6). In a multivariate
study on a cohort of children living in Peru, wealth displayed a negative correlation with
giardial infection (7). In other words, the diarrheal illness giardiasis was more strongly
associated with low-income neighborhoods. Moreover, diarrheal illnesses can be
associated with other risk factors such as access to clean water sources, sanitation, and
nourishment (7). Even though these diseases can be self-limiting, children are at a
disadvantage from recovering due to the aforementioned risk factors, making the
causes of diarrhea important public health and health disparity issues to address.
The zoonotic and waterborne diarrheal illness known as giardiasis is caused by the
protozoan intestinal parasite Giardia lamblia. Giardiasis is one of the most diagnosed
diarrheal illnesses worldwide, with around 280 million cases diagnosed per year (8). In
2012, about 15,000 cases of giardiasis were reported in the U.S. alone, with one third
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being hospitalized. Like other common diarrheal diseases, children under the age of 5
are disproportionately affected as seen in Figure 1. To further emphasize the prevalence
of this disease, it has been noted that children in developing countries have been infected
with giardiasis at least once in their lifetime (9). The infection could be either symptomatic
or asymptomatic (10). Acute symptoms of giardiasis include severe diarrhea, dehydration,
greasy stool, and abdominal cramps. Chronic symptoms can range from failure to thrive,
cognitive impairment, and arrested growth and development in children, as well as
irritable bowel syndrome in adults (11).

Figure 1. Annual number of cases and incidence rate of giardiasis by age in 2011-2012. The
annual number of cases and the incidence rate of giardiasis in 2011-2012 is the highest in children
under the age of 5 compared to the rest of the population (12). Figure adapted from the CDC.

The parasite is transmitted through food, water, and feces contaminated with
giardial cysts (10). It has a simple life cycle composed of two life stages as seen in Figure
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2: a binucleated, anaerobic teardrop-shaped trophozoite and an osmotically-resistant,
“dormant” oval-shaped cyst. Once ingested, the cyst transforms into trophozoites by the
process known as excystation. The trophozoites colonize the upper small intestine and
transform into cysts in the lower small intestine by encystation (10). The infectious cyst is
then transmitted in the environment and the cycle repeats (Figure 2).
In vitro encystation methods have made it possible to investigate encystation more
in detail (13,14). Part of the revelations associated with the encystation process are the
study of encystation-specific vesicles or ESVs. These vesicles are a part of a unique
secretory system in Giardia, which is considered a regulated pseudo-Golgi. The transport
and formation of these vesicles is a tightly regulated occurrence during encystation.
These vesicles are secreted and fuse to the plasma membrane to deliver Cyst Wall
Proteins (CWPs) and other cyst wall components (Figure 3) (15,16). For this reason,
ESVs are an important factor to consider when studying the parasite’s ability to
differentiate and generate infectious cysts.
Giardia is often a topic of interest because it is considered one of the earliest
unicellular eukaryotic cells and therefore serves as a model organism to study the origin
and evolution of life (17). The mechanism of pathogenesis utilized by Giardia leads to the
damaging of the intestinal mucosa and generating inflammatory responses (10). Since
the parasite has limited de novo lipid synthesis ability, it uptakes lipids from the hosts and
the environment for survival, replication, and encystation (17). However, the orchestrated
molecular mechanisms of transforming from trophozoite to cyst form (i.e., encystation) or
cysts to trophozoites (e.g., excystation) remain enigmatic.
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Figure 2. The simple dual life cycle of Giardia lamblia. Giardia has two life stages that are
the trophozoite and cyst form (9). A person contracts the disease by ingesting contaminated
food or water with cysts. The cysts excyst in the GI tract giving rise to two trophozoites. These
colonize the small intestine and absorb nutrients in the intestinal milieu. In the distal small
intestine, trophozoites encyst into the cyst form and are released into the environment through
stool and the cycle is left to repeat. Figure adapted from the CDC.
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Figure 3. The process of encystation or the transition of trophozoites to cysts. Panels A-D
demonstrate DIC images of encystation, while panels E-H show the localization of cyst wall
proteins during encystation. As seen in panel F, CWPs are localized to the encystation specific
vesicles (ESVs) and migrate to the cell’s periphery where they are integrated into the cyst wall.
The ESVs carry other necessary components of the cyst wall during encystation (15). Figure

adapted from Mendez et al. (2015).

1.2 The Sphingolipid Pathway in Giardia
Our laboratory, for the past several years is investigating the role of sphingolipids
(SLs) in regulating the encystation and cyst formation by Giardia. Sphingolipids (SLs) are
both important structural components of membranes and active signaling molecules that
are implicated in various cellular processes such as growth, differentiation, raft assembly,
apoptosis, senescence, and autophagy (18,19). For example, while SLs were found to
interact with growth-dependent signaling molecules in budding yeast (20), their cellular
accumulation in monogenic yeast caused mitochondrial dysfunction and cell death (21).
While early studies focused upon the role of entire SLs classes in cellular processes and
5

disease states, current evidences suggest that each molecule, i.e., ceramide (Cer) and
sphingomyelin (SM), is functionally distinct and regulate wide varieties of biological
functions (22-24). Various classes of glycosphingolipids accumulate in the midbodies and
cleavage furrows of dividing mammalian cells (25). A recent report indicates that SLs are
involved in maintaining a homeostatic balance of phosphoinositides (PIs) between transGolgi network and post-Golgi compartments, which is critical for Golgi-mediated cellular
trafficking (26). A previous study also suggests that SLs regulate the release of exosomes
that promote the clearance of amyloid- β fibril associated with Alzheimer’s disease (27).
Giardia is unique in the sense that only five SL metabolic genes have been
annotated in the genome database (Figure 4) (28,29), and their functional identities are
similar to eukaryotic SL enzymes (with low gene sequence identity). These five genes
include two copies of giardial serine-palmitoyltransferases (i.e., gspt-1 and gspt-2), one
copy of giardial glucosylceramide transferase gene (gglct1), and two giardial acid
sphingomyelinase-like phosphodiesterase genes (gasmasepd B and gsmasepd 3b). A
transcriptomic analysis revealed that all five genes are transcribed and expressed
differentially during encystation and cyst production (Figure 5) (30,31). Studies have also
indicated that while serine-palmitoyltransferase (gSPT) enzymes regulate ceramide (Cer)
endocytosis

in

Giardia,

glucosylceramide

transferase

(gGlcT1)

synthesizes

glucosylceramide (GlcCer), which regulates giardial cell cycle, membrane trafficking, and
encystation (32).
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Figure 4. The reduced sphingolipid biosynthetic pathway in Giardia. Of the 10 enzymes in
the eukaryotic sphingolipid pathway, Giardia only has the three enzymes annotated in blue due
to its compact genome (30). Figure adapted from Hernandez et al., (2008).

Figure 5. gGlcT1 expression is induced upon encystation. Immunoblot showing gGlcT1
expression during encystation. CWP2 expression was used as a comparison to confirm
induction of the encystation process. Antibodies used were against gGlcT1, CWP2, and PDI-2,
an ER marker, was used as a loading control (31). Figure adapted from Robles-Martinez et al.,
(2017).
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1.3 gGlcT1 Catalyzes the Synthesis of GlcCer and GalCer
It was demonstrated that the overexpression and knockdown of the gGlcT1
enzyme in Giardia interferes with the biogenesis of encystation-specific vesicles (ESVs)
and reduces the viability of cysts in culture (33). Interestingly, the normalization of gGlcT1
expression restores ESV biogenesis and cyst viability, further establishing the regulatory
role of gGlcT1 in encystation and cyst production. More recently, it was demonstrated
that gGlcT1 is a dual-substrate enzyme and catalyzes the synthesis of both
glucosylceramide (GlcCer) and galactosylceramide (GalCer), not lactosylceramide
(LacCer) (31). The chromatogram below is the result of an enzymatic assay with the
fluorescent substrate NBD-ceramide being converted into both GlcCer and GalCer
(Figure 6). The dual functionality of gGlcT1 was confirmed with bioinformatic analysis
(31). The analysis revealed that gGlcT1 contained two glucosylceramide transferase
(CGlcT) domains and one galactosylceramide transferase (CGalT) domain (Figure 7).
This is revelatory information because in higher eukaryotes and mammalian
species, there is an independent enzyme in charge of catalyzing each reaction. In
addition, these enzymes are localized to different organelle membranes with
galactosylceramide transferase on the ER and glucosylceramide synthase on the Golgi
apparatus (Figure 8) (34). Giardia not only has a compact genome, but it also lacks
emblematic eukaryotic organelles such as the Golgi, mitochondira, lysosomes, etc. (28).
This suggests that Giardia has adapted to a “minimalistic lifestyle” and uses one enzyme
for generating multiple products (35). For this reason, the giardial GlcT1 enzyme is an
advantageous target as it differs from the mammalian GlcT1, posing less risk for side
effects from a gGlcT1-targeting treatment.

8

Figure 6. gGlcT1 is a dual-substrate enzyme. Live cells were labeled with the fluorescent
substrate, NBD-Ceramide, to track product formation. Glycosphingolipids were extracted and ran
on a thin-layer chromatography (TLC) silica-coated glass plate. The chromatogram displayed
formation of both GlcCer and GalCer. It was thought that gGlcT1 could only catalyze the reaction
from UDP-glucose to ceramide (to produce GlcCer), but the enzymatic assay demonstrated it can
also transfer the galactose molecule from UDP-galactose to form GalCer (31). Figure adapted
from Robles-Martinez et al., (2017).
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Figure 7. Bioinformatic analysis confirms gGlcT1 has multiple potential catalytic
domains. Bioinformatics predicted two glucosylceramide transferase domains and one
galactosylceramide transferase domain (31). Figure adapted from Robles-Martinez et al.,
(2017).

Figure 8. Mammalians have independently localized enzymes for synthesizing
glucosylceramide and galactosylceramide. Unlike Giardia that has one enzyme catalyzing
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both reactions, higher eukaryotes and mammals have separate enzymes dedicated for each
reaction making gGlcT1 distinct enough that it can be used as a potential drug target (31,34).
Figure adapted from Ichikawa & Hirabayashi, (1998).

1.4 gGlcT1 and Lipid Homeostasis
It has been shown previously that gGlcT1 overexpression elevates the intracellular
levels of lipids and fatty acids in trophozoites (32,33). Duarte et al. (2019) demonstrated
that Giardia has dynamic sphingolipid metabolic pathways which alters during the
transition from trophozoites to cysts (36). Ellis et al. recently found that lipid profiles in
trophozoites and cysts are substantially different from each other (37). It further
suggested that lipid metabolism in cysts is highly active and generates membrane lipids
with long-chain fatty acyl moieties (37), suggesting that rapid membrane remodeling
occurs during excystation. Since lipids are involved in membrane synthesis, it is likely that
gGlcT1 plays a critical role in regulating lipid compositions of membranes (trophozoites
and cysts). In another experiment, we found out that in-vitro cysts that were derived from
different gGlcT1 expression cell lines (i.e., Endo-gGlcT1-HA, α2-Tub-gGlcT1-AU1, and
OCT-gGlcT1-HA) (please see the methods section for additional information) displayed
different levels of lipids in wild type and gGlcT1 over expression with two different
constructs (Figures 11-12). These results (unpublished) indicate that the modulation of
gGlcT1 activity affects lipid profiles in cyst and this could be associated with cyst viability
and excystation by Giardia. This is interesting because Giardia has a limited lipid
synthesis ability and mostly depends on supplies from outside (17,38,39). To further
understand this phenomenon, we searched the genome database (GiardiaDB) and found
that it has only one copy of long chain fatty acid elongase gene (gfaelo; GL50581_2228)
11

that could participate in lipid remodeling reactions induced by gGlcT1 (30). A sequence
alignment of this gene found it had remarkable similarity to elongase genes of the thale
cress plant Arabidopsis thaliana and another protozoan Entamoeba histolytica, but not
the human gene (Figure 9).
Because long-chain fatty acids (LCFAs) participate in the remodeling of glyceroland sphingosine-based phospholipids, membrane regeneration and dynamics (40), and
cyst membranes undergo a dramatic reorganization becoming the plasma membrane of
trophozoites (41), we cloned and overexpressed gFAELO in gGlcT1 expressing cells and
monitored cyst formation to elucidate the interplay and regulation between these two
enzymes. Labeling cysts with a cholera-toxin conjugate as a marker for the plasma
membrane demonstrates how this membrane becomes the membrane of newly-excysted
trophozoites or excyzoites (Figure 10) (41).

Figure 9. gFAELO sequence alignments shows similarity to A. thaliana and E. histolytica.
Comparing the only giardial fatty acid elongase reveals great similarity to multiple elongase
genes of Arabidopsis thaliana and another protozoan, Entamoeba histolytica.
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Trophozoite

Cyst

Figure 10. The cyst plasma membrane becomes the plasma membranes of excysted
trophozoites. The excystation process of Giardia involves reorganization of the inner cyst
membrane to give rise to two excyzoites (41).

1.5 Current Treatments and Drug Resistance Phenomena
As no vaccines are currently available to treat giardiasis, chemotherapeutic agents
are the only options to control infection. The 5-nitroimidazole, metronidazole
(Mtz,Flagyl®), is a commonly prescribed treatment for giardiasis. Although drugs such as
tinidazole (5-nitroimidazole), nitazoxanide (nitrothiazole), albendazole (benzimidazole),
and mebendazole (benzimidazole) are also used for treatment, they all may cause side
effects (42). For example, Mtz is a genotoxic agent and a potential carcinogen, and its
frequent use gives rise to drug-resistant giardiasis. Refractory or reoccurring giardiasis in
endemic areas can lead to a drug resistance rate in up to 70% of cases (43). Other drugs
from the nitrothiazole and benzimidazole groups are also used, but like Mtz, they can
produce toxicity and may interfere with pregnancy (42). Among the non-metronidazole
classes of compounds, several repurposed drugs such as auranofin, fumagillin
(antibiotic), orlistat, omprezole, disulfirum, and NBDHEX have showed promising activity
against the Giardia parasite in culture (42). In addition to drug resistance and side effects,
13

poverty poses a barrier to treatment. This is especially problematic in developing
countries where clean water is difficult to access (10). This public health issue makes it
an urgent matter to find a new target for giardiasis treatment. I propose that gGlcT1 is
unique and could serve as a novel target for developing anti-giardial agents in the future.

1.6 Specific Aims and Hypothesis
The overall goal of my research is to delineate the role of gGlcT1 in Giardia and
the mechanism by which it regulates encystation and cyst production. I will be
investigating: (1) whether both GlcCer and GalCer transferase activities are essential for
inducing encystation; (2) if the regulated expression of gGlcT1 and gFAELO is critical for
cyst morphology and viability. Therefore, this project aims to understand the function of
gGlcT1 at the molecular level and its role in maintaining giardial virulence to pave the
path for a more specific therapeutic target against giardiasis.
Specific Aim 1: Characterization of GlcT1 by molecular and biochemical
methodologies. My preliminary results show that gGlcT1 is unique because: (1) it can
catalyze the synthesis of glucosylceramide (GlcCer) and galactosylceramide (GalCer)
and (2) consists of separate domains of ceramide-glucosyltransferase (CGlcT) and
ceramide-galactosyltransferase (CGalT). I have also observed promoter-specific
expression of CGlcT and CGalT, implicating that these two domains act differently and
could regulate different sets of cellular functions. Site-directed mutagenesis assays will
be carried out in attempts to uncover the active site residues important for its dualsubstrate activity. These results will be important to determine the function of each
domain and their effects on cyst production, viability, and infection.
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Specific Aim 2: Investigate the modulation of cyst morphology by gGlcT1
and a possible interplay with long-chain fatty acid elongase (gFAELO). The impact
of the GlcT1 enzyme in context of giardiasis will ultimately be determined by cyst virulence
in mouse models. For the parasite to induce infection in mice, the cysts have to be viable
in terms of having the ability to excyst in the organism and encyst once again before being
excreted. Because the different gGlcT1 clones generated in Specific Aim 1 show
differential enzymatic activities, my goal is to test their impact on cyst morphology.
Impact: The proposed study will provide an in-depth understanding of the gGlcT1 and
the possibility to use it as a target of drug development.
I hypothesize that elucidating the function of glucosylceramide transferase
will reveal the mechanisms of giardial differentiation and could be exploited to
design novel drugs against this pathogen.
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2. METHODS
2.1 Giardia Culture
Giardia trophozoites (strain WB, ATCC No. 30957) were cultured in TYI-S-33
medium supplemented with adult bovine serum (ABS, 5%) and bovine bile (0.5%) at 37◦
C. The antibiotic piperacillin (100 μg/ml) was added during routine culturing of the
parasite (44). Antibiotics such as blasticidin (50 μg/ml), neomycin (150 μg/ml), and
puromycin (50 μg/ml) were also used for culturing endogenous and episomally-tagged
gGlcT1 cells. Trophozoites were harvested by scraping and centrifuged at 1,500 x g for
5 minutes at 4◦C, followed by three phosphate-buffered saline (PBS) washes. In vitro
encystation was carried out following the method described earlier (13). Briefly,
trophozoites were cultured in TYI-S-33 medium with (pH 7.8) containing adult bovine
serum (10%), lactic acid (10%), and porcine bile (5%) (13). Cells were allowed to encyst
for 72 hours (h) and harvested by centrifugation at 1,000 x g for 5 minutes at 4◦C,
followed by subsequent sterile water washes to isolate water-resistant cysts.

2.2 Plasmid Construction
A plasmid containing an a-tubulin promoter with an AU1 epitope was obtained
from Dr. Chin-Hung Sun, Taiwan (45). The plasmid pKS-3HA-BSR was used to
incorporate the endogenous tag plasmid (46). The giardial Mad2 gene (a mitotic check
point protein, GL50803_100955) was previously incorporated to insert AscI and FseI
restriction sites. The entire open reading frame of gglct1 (GL50803_11642) was
amplified and cloned into the plasmid using the primers: 5’
CGCGAAGCTTGGCCGGCCATGGACGGGTTGACTCTCTCC 3’ and 5’
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GCGCCTCGAGCGGCGCGCCGTCGAGGGATTTTTTATTGGC 3’. The insert and
plasmid were digested with AscI and FseI and ligated together, replacing the Mad2
gene (Figure 11).
The plasmid pPAC-OCTp-ANX3-3xHA-C (ornithine-carbamoyl transferase)
promoter plasmid was developed in a similar procedure (Figure 12) (47). The giardial
ANX3 gene was digested from the plasmid using BamHI and NotI and was replaced with
the open reading frame of gglct1 that was obtained by using the primers 5’
AAAAAGGATCCGACGGGTTGACTCTCTCCTT

3’

and

5’

AAAAA

GCGGCCGCGCGTCGAGGGATTTTTTATT 3’, with the BamHI and NotI sites underlined
respectively. gfaelo (GL50581_2228) was cloned in the same manner using the primers
5’

AAAAAGGATCCGCTGGCTGGTCATGGCTTCA

3’

and

5’

AAAAAGCGGCCGCGCATTAACCATTTCAGTGCAA 3’. The start codon was already in
the plasmid and the base pairs in red had to be inserted to compensate for a frameshift.
Plasmids were transformed into chemically competent DH5a E. coli cells and plated onto
LB plates with 100 ug/ml ampicillin. Colonies were screened by PCR and sequenced at
the UTEP DNA Sequencing Core facility. A maxiprep was then performed to ensure
sufficient quantity of DNA to be electroporated. Successful endogenous HA tag clones
were linearized with FseI prior to electroporation for homologous recombination (46).
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Figure 11. The constructs that were used to incorporate an endogenous HA tag into gGlcT1
and gFAELO, respectively. The pKS constructs without a promoter were used to homologously
recombine at the endogenous locus in Giardia to insert the hemagglutinin epitope tag (46).

A

18

B

Figure 12. Overexpression constructs used for gGlcT1 and gFAELO modulation. (A) OCT
promoter constructs were used for overexpression of gGlcT1 and gFAELO, while the (B) a-tubulin
promoter construct was used to coexpress gGlcT1 with gFAELO (45,47).

2.3 Generation of mutant cell lines
Instructions were followed according to the QuikChange II XL kit (Agilent) to
truncate the gglct1 gene in the OCT promoter-3x HA tag plasmid (Figure 13A).
Complimentary primers were designed to flank the region of deletion, with 15 bases of
the gene sequence on both sides. Using the gglct1 sequence alignment as a guide, the
deletions were chosen to be amino acids 54-80 (-CGlcT1), 148-179 (-CGlcT2), and 242267 (-CGalT) as seen in Figure 13B (31). The primers for the deletions were the
following: 5’ GTCGTTCTGCCCTGC GTGTACGTTGTTGAG 3’ and 5’
CTCAACAACGTACAC GCAGGGCAGAACGAC 3’; 5’ CTCGAAGCTCACAG
AGCCTTGTGTTTGCC 3’ and 5’ GGCAAACACAAGGCT CTGTGAGCTTCGAG 3’; 5’
GTCCCTTTTTGCTGG TATTCAGAGGACAC 3’ and 5’ GTGTCCTCTGAATA
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CCAGCAAAAAGGGAC 3’. Colonies were screened by PCR and sequenced at the
UTEP DNA Sequencing Core facility. The primers used for sequencing or confirming
the domain deletions were 5’ CAAGAATCGTCCAAGGGTTA 3’ (-CGlcT1), 5’
CATGCTAGAGACGTCTCCTC 3’ (-CGlcT2), and 5’ CCAGCTCATAATGGTCTACC 3’ (CGalT). A maxiprep was done on each clone to gather sufficient DNA material for
electroporation.
A

B

Figure 13. Domain deletion strategy and notation. (A) The QuikChange II XL kit was used

with primers flanking each domain to generate OCT promoter constructs with mutant
gGlcT1. (B) The deletion mutants are referred to as -CGlcT1, -CGlcT2, and -CGalT,
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indicating removal of the glucosylceramide or galactosylceramide transferase domains.
2.4 Transfection of Giardia trophozoites
Approximately 1x107 trophozoites were resuspended in 300 μl of complete TYI-S33 medium (pH 7.1) with 40 μg of plasmid and inserted into 4-mm electroporation
cuvettes (31). Trophozoites were transfected by electroporation on a BioRad Gene
Pulser X cell (BioRad, Hercules, CA) using the following parameters: 322 V, 500 μF,
and ∞Ω resistance (4-mm cuvette). Cells were then allowed to recuperate in media
overnight, followed by selection with blasticidin (100 μg/ml), puromycin (100 μg/ml), or
puromycin and G418 (150 μg/ml) (Fisher & Sigma Aldrich, St. Louis, MO). Media was
replaced every three to four days. Stable transfectant trophozoites overexpressing
gGlcT1 were established within two weeks.

2.5 Immunoblot
Cell lysates were prepared by incubating in hypotonic buffer for 30 minutes (5
mM HEPES-pH7.4, 0.5 mM EDTA, 0.1% Triton X-100) on ice followed by adding lysis
buffer (50 mM HEPES, pH7.4, 250 mM sucrose, 25 mM KCl and 5 mM MnCl2, 10 uM
E64, and a protease inhibitor cocktail). Samples were sonicated using a 1/8” probe for 3
minutes with a 37% amplitude and 3 sec/9sec pulse-rest and passed through a 27-G X
1 1/4 needle 20 times. Protein concentration of cell lysates were determined using the
Bradford assay (BioRad) and 30-40 μg of protein were boiled with 2x Laemmli Buffer
and β-mercaptoethanol (BME) at 90°C for 5 minutes. The samples were then applied
onto a polyacrylamide gel (10%) for 2 hours at 100V and 300 mA followed by an
immunoblot analysis for 35 minutes at 110 V and 300 mA. The PVDF membrane was
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then incubated overnight in the cold room with 5% milk/TBST (25 mM Tris-pH 7.5, 500
mM NaCl,0.1% Tween 20) with a primary antibody. The mouse HA antibody (SIGMA)
was used to detect HA-tagged gGlcT1 (dilution 1:1,000), while tubulin was detected
from a mouse tubulin antibody that was a gift from Dr. Giulio Francia (dilution 1:100).
The next day, the blots were washed three times with TBST buffer and incubated in the
secondary antibody (Thermo) for an hour at room temperature (dilution 1:2,000). After
three TBST washes, blots were covered with ECL solution (100 mM Tris-pH 8.8, 2.5
mM luminol, 0.4 mM 4-IPBA, 2.6 mM H2O2) and exposed using the iBright machine
(Invitrogen).

2.6 Assessing cyst viability via flow cytometry
Water resistant cysts were stained with 1 mg/ml propidium iodide (PI) in PBS
(Acros Organics). Samples were run on the Beckman Coulter Gallios flow cytometer.
Gates were adjusted using control samples of 4% hydrogen peroxide treated cysts
stained with PI and untreated cyst samples.

2.7 Determination of gGlcT1 activity by live-cell labeling
Live-cell NBD-ceramide labeling assay was performed to measure the gGlcT1
activity (Figure 14) (31). Briefly, ~1x107 trophozoites were harvested and incubated in
PBS for an hour at 37°C, shaking. The cells were then spun down at 1,500 g for 5
minutes and resuspended and incubated in 1.5 ml of incomplete DMEM media and 5 ul
of 0.5 mM NBD-ceramide/BSA (Invitrogen) for 3 hours at 37°C with slow shaking.
Glycosphingolipid (GSL) extraction was performed on the cell pellet by adding 1.3 ml of
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water, 1.3 ml of chloroform, and 1.3 ml of acetic acid/methanol (1:50 v/v) into cell
pellets. The tubes were vortexed for 1 minute and spun at 3,000 x g for 10 minutes. The
bottom organic layer was transferred to a new tube, and 1.3 ml of chloroform was added
to the original sample for another round of trace lipid extraction. Again, the tubes were
vortexed and centrifuged in order to pool the second organic layer with the first one. The
samples were dried for 20 min. under N2 and resuspended in 80 ul of
chloroform/methanol (1:1 v/v). 20 ul of the sample was spotted onto a silica gel 60 thinlayer chromatography (TLC) plate along with various concentration of standard lipids
such as NBD-ceramide, NBD-glucosylceramide (NBD-GlcCer), NBDgalactosylceramide (NBD-GalCer), and NBD-lactosylceramide (NBD-LacCer)
(Invitrogen and Matreya). The mobile phase for the chromatography was propanol, ethyl
acetate, ammonium hydroxide, and water 75:5:5:25 (v/v/v/v). The plate was placed into
a chamber for 2 h at room temperature and then dried for 20 minutes, prior to capturing
images with the help of the GelDoc imager (BioRad). Fluorescent chromatograms were
analyzed using the ImageJ software.

Figure 14. Flow-chart of the live-cell labeling with NBD-Ceramide protocol. Trophozoite or
encysting cells were collected and starved, before being labeled with the fluorescent substrate
NBD-Ceramide. The glycolipids were extracted and ran on a silica plate before being imaged and
quantified on imaging software.
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2.8 Confocal Microscopy
Trophozoites, encysting cells, and cysts were harvested and washed. Cell pellets
were fixed in 50 μl PBS mixed with 250 μl of 4% paraformaldehyde for 10 minutes (33).
Following PBS washes, the samples were blocked with normal goat serum (5%) for 20
min at room temperature. This was replaced with cyst antibody (Santa Cruz sc-57744)
at a dilution of 1:100 in 1% NGS and incubated overnight at 4°C. Cells were washed
with PBS before incubating with secondary anti-mouse antibody for an hour at room
temperature in the dark at a dilution of 1:400 (Alexa Fluor 568, Invitrogen). Following
PBS washes, 50 μl of 1 μg/ml DAPI was added and incubated for 15 minutes. Cells
were then resuspended in PBS and mounted with Vectashield Antifade mounting
media. Samples were imaged and analyzed (n=30) using the LSM 700 laser scanning
confocal microscope and software (Carl Zeiss).

2.9 Statistical Analysis
Statistical analyses were performed using the GraphPad Prism software. Data
sets were processed using one-way or two-way ANOVA with Tukey’s multiple
comparisons. *p<0.05, ** p<0.01, ***p<0.001, ****p<0.0001.
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3. RESULTS
3.1 Specific Aim 1: Characterize gGlcT1 by molecular and biochemical methodologies
3.1.1 Modulation of gGlcT1 expression in Giardia
Previous work from our laboratory has demonstrated that gGlcT1 expression is
elevated during encystation and its unregulated expression interfered with ESV
biogenesis and cyst production (31,33). In our previous experiments, we used an
overexpression gGlcT1 plasmid that contained a weak α2-tubulin promoter. This
promoter was found to be active when the cells were subjected to stimulation for
encystation. Using this plasmid, Robles-Martinez et al., demonstrated that Giardia
preferably expresses CGalT activity rather CGlcT, indicating that promoter-specific
expression of CGlcT and CGalT domains are possible (31). Since gGlcT1 synthesis is
induced during encystation and overexpression (~3 fold) of gGlcT1 under a2-tubulin
promoter decreased cyst production and viability (33), I examined whether the expression
of this enzyme in trophozoites with the help of a strong promoter would have an impact
on cyst production and cyst viability. Therefore, gGlcT1 was overproduced under a strong
ornithine-carbamoyl transferase (OCT) promoter (48). The construct pPAC-OCTp-ANX33xHA-C was obtained from Dr. Svärd (University of Uppsala) (47). Side by side, I also
tagged endogenous gGlcT1 by homologous recombination as described in the “Methods
Section,” using a construct (pKS-3HA-BSR) obtained from Dr. Alex Paredez (University
of Washington) (46). Conventionally, gGlcT1 levels increase during encystation, OCTpgGlcT1-HA driven by the OCT promoter was expressed in trophozoites and encysting
cells, but its expression was dramatically reduced in cysts (Figure 15).
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Figure 15. OCT promoter overexpression cells show a unique gGlcT1 protein profile
during differentiation. Immunoblot of cells under the OCT promoter display gGlcT1 expression
in trophozoites and encysting cells, but significantly lower in cysts. On the contrary, cells
carrying Endo-gGlcT1-HA showed the synthesis of gGlcT1 in a stage-specific manner. Troph,
trophozoites; E24, Cells with post-induction of encystation for 24 hrs (24h PIE)
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3.1.2 Dissecting the function gGlcT1 catalytic domains
To determine which domain was more critical for enzymatic function, each domain
was deleted utilizing site-directed mutagenesis. Figure 16 compares the changes seen
in trophozoites, encysting cells, and cyst production of the 5 different clones expressing
gGlcT1. These 5 clones are the: (1) endogenous-tagged gGlcT1, (2) OCT promoter
overexpressing gGlcT1, and the three truncation mutants under the OCT promoter (CGlcT1, -CGlcT2, and -CGalT). Trophozoite growth was tracked for a total of 32 hours,
with counts every 8 hours to account for doubling time. I observed that while trophozoites
showed more or less similar growth patterns, parasites lacking either catalytic domain (CGlcT1 or -CGalT) drastically reduced the production of cysts (Figure 16A and 1C).
Interestingly, however, the deletion of these catalytic domains didn’t interfere with the
biogenesis of the encystation-specific vesicles (ESVs) as their counts among cell lines
remained unchanged (Figure 16B).
The next step was to determine the viability of the cysts that were produced by
Giardia cells with deleted catalytic domains. For this, water-resistant cysts isolated from
all the cell lines were stained with PI and subjected to flow cytometry analysis as
described in the Methods Section. Incidentally, no significant difference in viabilities were
observed in gGlcT1 mutant clones as shown in Figure 17. Although less cysts were
produced with mutant cells, their viability was consistent indicating that they retained the
ability to excyst.
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B

C

Figure 16. Comparison of the trophozoite growth and production of ESVs and cysts for
the various clones of Giardia expressing gGlcT1. (A) Giardia cell lines were cultured in TYI-
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S-33 medium supplemented with bovine serum (5%) and bovine bile (0.5%). The growth was
initiated with 1X104 cells, and the growth was monitored for 32 hours (~4 doubling times) by
counting with the help of a hemocytometer. (B) Giardia trophozoites were encysted for 24 hours
in encysting media. They were harvested after 24 hours and fixed with 4% PFA before they
were stained with cyst antibody (SC-57744) and Alexa 568. The number of encystation-specific
vesicles (ESVs) were counted per cell. There was no significant difference among cell lines. (C)
5X106 trophozoites were cultured in TYI-S-33 medium with pH 7.8 and 10% adult bovine serum,
10% lactic acid, and 5% porcine bile. Quantification of cyst production after encystation for 72
hours showed a significant difference in the cyst production of mutants without the CGlcT1 or
CGalT domains.

Figure 17. Comparison of the cyst viability of the gGlcT1 cell lines. Water-resistant cysts were
subjected to propidium iodide staining and ran in the flow cytometer after a brief incubation. Cyst
viabilities did not change among gGlcT1-expressing cell lines and mutants. Data analysis was
performed with a one-way ANOVA and Tukey’s multiple comparison test. ** p<0.01, ***p<0.001.
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3.1.3. Analysis of reaction products
For the analysis of reaction products, wild type, overexpressed, and mutant
(Figure 18A) gGlcT1 trophozoites were subjected to encystation for 24 hr (24 PIE)
followed by in vivo labeling with fluorescently conjugated NBD-ceramide (31). The
product formation was maximum when overexpressed cells were used and both GlcCer
and GalCer were produced (Figure 18B-C). Although GlcCer levels were higher
compared to GalCer, Figure 18B-C indicates that the CGlcT1 and CGalT domains are
active because deletion of these domains reduced the product formation as evidenced
by the fluorescent chromatogram and the quantification of the bands. There was no
overall difference in galactosylceramide production among cell lines, but it is important
to note that this product formation is induced upon encystation (data not pictured).
These results indicate that there is a coordinated expression of both CGlcT and CGalT
domains that regulate the activity of gGlcT1 during the growth and encystation of
Giardia.
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Figure 18. Enzyme activity is increased in the overexpression cell line but reduced in
mutants -CGlcT1 and -CGalT. (A) Corresponding notation for each deletion mutant. (B) Thinlayer chromatography plate displaying the glycosphingolipids labeled with fluorescently labeled
NBD-Ceramide. T, trophozoites; E24, 24 hr PIE. (C) Quantification of enzyme activity assayed by
thin-layer chromatography. Data analysis was performed with a two-way ANOVA and Tukey’s
multiple comparison test. *p<0.05, ** p<0.01, ***p<0.001.
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3.2 Specific Aim 2: Investigate the modulation of cyst morphology by gGlcT1 and a
possible interplay with long-chain fatty acid elongase (gFAELO)
3.2.1 Cyst wall thickness, area, and diameter is affected by gGlcT1 mutations
Cyst morphology is a determinant for the giardial cyst to survive the environment
and excyst upon entering hosts (41). An intact and thick cyst wall is critical for
preventing permeability of water, solutes, and other molecules to sustain the tonicity
allowing the resistant cysts to withstand environmental conditions. It has already been
shown that deleting either CGlcT1 or CGalT results in decreased cyst production. With
this in mind, a confocal analysis was performed to determine the changes in cyst
morphology, including the cyst wall thickness to determine whether specific gGlcT1
domains are important in the cyst composition. Water-resistant cysts were fixed and
stained with CWP antibody to stain the cyst wall with conjugate Alexa fluor 568. The
immunostaining of cysts can be seen in Figures 19A-E. Cyst measurements were
taken from multiple frames and were documented. Cyst diameter and cyst area of cysts
without the CGlcT2 domain remained similar to wild-type (Figure 19F-G). Overall, cysts
without the CGlcT1 and CGalT domain resulted in smaller cysts with a thinner cyst wall
(Figures 19F-H). This data shows that the CGlcT1 and CGalT domains are not only
important for cyst production and enzymatic activity, but also cyst morphology.
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Figure 19. Changes in Cyst Parameters from gGlcT1 deletion mutations. (A) Cyst confocal
images of Endo-gGlcT1-HA, (B) OCTp-gGlcT1-HA, (C) -CGlcT1, (D) -CGlcT2, and (E) -CGalT
cysts. (F-H) Cyst wall thickness, cyst area, and cyst diameter among the different expressions of
gGlcT1 demonstrate that -CGlcT1 and -CGalT cysts are smaller with a thinner cyst wall. Data
analysis was performed with a one-way ANOVA and Tukey’s multiple comparison test. *p<0.05,
** p<0.01, *** p<0.001, **** p<0.0001.
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3.2.2 Interplay between glycosphingolipid production and lipid remodeling
It has been reported that excess production of gGlcT1 increases lipid and fatty
acid uptake by Giardia and that alters its overall lipid homeostasis (33). However, the
mechanism of gGlcT1-induced changes of lipid homeostasis is not clear. Since the
long-chain fatty acids (LCFAs) participate in the remodeling of glycerol- and
sphingosine-based phospholipids and membrane regeneration and dynamics, we
cloned and overexpressed giardia fatty acid elongase- 1 gene (gfaelo-1,
GL50581_92729) in Giardia (39). It was also expressed under an OCT promoter by
itself and transfected into cells with α-TUB-gGlcT1-AU1.
Immunoblot analysis showed that it is expressed in cysts but becomes
constitutively expressed with the co-expression of +gGlcT1 (Figure 20A). This interplay
was seen in the trophozoite growth, as these cells grew slightly faster or had an
increased doubling rate when compared to wild type endogenously tagged cells and
overexpressing gFAELO cells (Figure 20B). The impact of gFAELO was also seen
when cyst production was measured in these cell lines. Overexpressing gFAELO on its
own resulted in the least amount of cyst production and this phenotype was only slightly
rescued upon the coexpression of gGlcT1 (Figure 20C). Altogether this data indicates
that overexpressing gFAELO impacts cyst production, and when it is overexpressed
with gGlcT1, the interplay between both enzymes leads to overall metabolic changes
giving rise to changes in both trophozoite growth and cyst production. The phenomenon
of a distinct global profile was seen in a PCA of extensive lipidomic analysis in cysts
(unpublished).
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Figure 20. Coexpression of gFAELO and gGlcT1 alters gFAELO expression, trophozoite
growth, and cyst production. (A) Overexpressing gGlcT1 under the alpha-tubulin promoter (αTUB-gGlcT1-AU1) and gFAELO under the OCT promoter (OCTp-gFAELO-HA) induces
constitutive expression of gFAELO. (B) Trophozoite growth was higher in gFAELO and gGlcT1
co-expressing cells. (C) Cyst production was decreased when gFAELO was overexpressed alone
or in conjunction with gGlcT1. Data analysis was performed with a one-way ANOVA and Tukey’s
multiple comparison test. *p<0.05, ** p<0.01

To determine the effects on cyst morphology, water-resistant cysts were once
again fixed and stained against the giardial CWP, bound to the conjugated Alexa fluor
568 (Figure 21A-C). It was found that cysts derived from gFAELO overexpressed cells
are slightly larger with relatively thinner cyst walls, suggesting the gFAELO expression
in cysts could be linked to excystation (Figure 21D-F). On the other hand, coexpression
of gGlcT1 with gFAELO reverses the proves, further implicating that gFAELO and
gGlcT1 are co-regulated and interact especially when it comes to cyst production and
morphology. Confocal images and analysis demonstrated that overexpressing gFAELO
with or without gGlcT1 influences cyst wall thickness, area, and diameter (Figure 21).
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Figure 21. Change of Cyst Parameters by gGlcT1 and gFAELO. (A) Cyst confocal images of
Endo-gFAELO-HA, (B) OCTp-FAELO-HA, and (C) α-TUB-gGlcT1-AU1 and OCTp-FAELO-HA
cysts. (D-F) Cyst wall thickness, cyst area, and cyst diameter measured among different
expression parameters of gGlcT1 and gFAELO. Data analysis was performed with a one-way
ANOVA and Tukey’s multiple comparison test. ** p<0.01, **** p<0.0001.
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4. DISCUSSION
Glucosylceramide transferase (GlcT1) is an evolutionarily conserved enzyme
across eukaryotes and protozoan parasites. It is responsible for forming one of the most
basic glycosphingolipid (GSL) building blocks, glucosylceramide (GlcCer) by combining
UDP-sugar and ceramide as follows:
GlcT1
UDP-Glucose + Ceramide

à

Glucosylceramide

The enzyme has been implicated for its role in cell proliferation and multi-drug resistance
in cancers including but not limited to breast, neuroblastoma, melanoma, colon, and lung
cancer (49-53). Inhibiting the expression of gGlcT1 makes cells more susceptible to
chemotherapy and apoptosis (54-59). It has also been implicated in restoring insulin
sensitivity and protective effects on renal and neuronal tissue (60-62). Therefore, it is
being considered as a promising drug target in future cancer, renal hypertrophy, diabetes
type 2, Parkinson’s, and Alzheimer’s treatments.
In Giardia, gGlcT1 is an ER membrane protein (number of amino acids: 537; MW:
~55-60 kD) and sufficiently diverged from mammalian GlcT1. Pharmacological and
molecular interference of gGlcT1 inhibits the attachment, growth, and encystation (30,32).
Our two laboratories used a small molecule inhibitor called PPMP (threo-1-phenyl-2palmitoylamino-3-morpholino-1-propanol) to inhibit the enzyme activity in Giardia. PPMP
is a known inhibitor of GlcT1 with therapeutic potential against cancer (63). Štefanić et al.
demonstrated that PPMP inhibited the attachment, replication, and encystation of Giardia
in culture (32). Although it didn’t interfere with the cell cycle progression, they also found
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that PPMP blocked cytokinesis in trophozoites. Our laboratory, on the other hand,
demonstrated that PPMP inhibited the cyst production by blocking the expression of the
gglct1 gene and also the nuclear division or karyokinesis of cysts (30). Furthermore, both
Štefanić et al. and our laboratory demonstrated that gGlcT1 affects the lipid synthesis and
remodeling in Giardia trophozoites (32,33). However, the most fascinating aspect of
gGlcT1 function was demonstrated by Mendez et al., who showed that the molecular
modulation of gGlcT1 by overexpression and knockdown (using anti-gGlcT1 morpholino
oligonucleotide) blocked ESV biogenesis and cyst production by Giardia in culture (33).
Robles-Martinez et al. conducted a detailed analysis of this enzyme and found that
gGlcT1 can catalyze the synthesis of two products (Figure 6)—GlcCer and GalCer, but
not mannosylceramide (ManCer) or lactosylceramide (LacCer) (31). This was an
important observation as there currently is no galactosylceramide transferase (CGalT)
enzyme annotated in the Giardia genomic database. Therefore, my dissertation work
aimed to further characterize the mechanism of this enzyme in its role of Giardia
differentiation and cyst production/viability. The objectives of my dissertation are: (1) to
dissect the functions of the two catalytic domains on regulating the cyst formation and
cyst wall biosynthesis, and (2) to investigate how gGlcT1 function is downregulated in
cysts, which is critical for the successful excystation.
To fulfill the first objective, I employed a plasmid with a strong and natural promoter
(OCT) containing gGlcT1 with hemagglutinin (HA) tag (Figure 12A) provided by Dr.
Staffan Svärd (Uppsala). Using this newly assembled plasmid (OCT-gGlcT1-HA), it was
possible to overexpress gGlcT1 in trophozoites as shown in Figure 15. Interestingly, it
was observed that early expression of gGlcT1 in trophozoites prevents the synthesis of
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this enzyme in cysts, in contrast to wild type, where gGlcT1 was mostly expressed in
encysting cells and cysts (Figure 15). The same expression pattern of gGlcT1 in wild type
was also observed with the plasmid (α2-tubulin-gGlcT1-AU1) that was used by Mendez
et al. and Robles-Martinez et al. and shown in Figure 5 (31,33). Although the reason for
this discrepancy of gGlcT1 expression with OCT-gGlcT1-HA is still not clear, it is possible
that the early expression of this encystation-specific protein in non-encysting trophozoites
could be an obstruction for the smooth transition of trophozoites to cysts, and therefore,
is degraded by proteasomal degradation pathways (64). This observation can be further
supported by the results of increased gGlcT1 activity in overexpressed cells (Figure 18),
the reduction of cyst production (Figure 16) without affecting cyst viability (Figure 17),
and the impact on cyst morphologies (Figure 19). Interestingly, cell lines lacking either of
the catalytic domains revealed reduced enzymatic activities, decreased cyst production,
and affected cyst parameters, specifically the thickness of the cyst walls, indicating both
domains contribute significantly to cyst formation and cyst structures. Together they
ultimately dictate the overall functions of the gGlcT1 enzyme (Figures 16-19).
The reduction of cyst formation and decreased cyst wall thickness by gGlcT1
mutant Giardia cell lines suggest that there should be a mechanism of controlling gGlcT1
expression that is critical for driving the process of excystation (Figures 16 and Figure
19). Since cysts are metabolically active and show a robust change of lipid profiles (Ellis
et al., unpublished), we thought fatty acid elongase (gFAELO) could be involved in this
event and responsible for the downregulation of gGlcT1 during excystation. Therefore, I
expressed gFAELO and monitored its expression in trophozoites and encysting cells
(Figure 12A). Figure 20A demonstrates that gFAELO is not expressed in trophozoites.
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Its expression increases with encystation and is expressed predominantly in cysts. To
further explore the idea if gGlcT1 and gFAELO interact, I co-expressed these two genes
and monitored by western blot analysis (Figure 12). Results demonstrated that the coexpression changed the profile of gFAELO expression and instead of cysts, its synthesis
was observed in all stages (Figure 20A). As far as cyst production is concerned, gFAELO
reduced the production of cysts and generated cysts with thinner cyst walls (Figure 20C
and Figure 21). This observation is in good agreement with our hypothesis that gFAELO
might be associated with the excystation process. Co-expression of gFAELO with gGlcT1
slightly improves the effect of gGlcT1 (i.e., the formation of cysts with thick cyst walls in
Figure 21). These results indicate that gGlcT1 and gFAELO may have opposite effects
of each other. While gGlcT1 facilitates the cysts formation, gFAELO participates in
excystation and the interplay between these two enzymes are critical for running the
encystation-excystation cycle of Giardia.
4.1 Final Overview
Taking all the data into consideration, it is evident that gGlcT1 and gFAELO have
important roles in the life cycle of Giardia. It was found that gGlcT1 affects giardial
differentiation and cyst morphology, leading to implications in the ability for the parasite
to withstand environmental conditions for transmission. It was also observed that the
enzyme may have domain-specific enzymatic activity, and its interaction with the
gFAELO enzyme involved in lipid remodeling may lead to a role in excystation as well.
In this study, the implication of glucosylceramide synthase/transferase was further
elucidated in the context of encystation and overall cellular function in Giardia.
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From deleting domains in gGlcT1 and modulating gFAELO expression, it was
found that although cysts resist water and their viability remained the same, they are
ready and able to excyst and infect (Figures 19 and 21). Since cellular conditions are
being changed, it was hypothesized that this would cause perturbations to the parasite’s
livelihood. gGlcT1 is induced upon encystation and it needs either its first or third
catalytic domain in order to produce its products glucosylceramide and
galactosylceramide. Modulating expression or eliminating these domains has been
shown to decrease cyst production and altered cyst morphology. In the same manner,
overexpressing gFAELO lead to similar results but with greater importance in
excystation. It is the enzymes’ impact on cyst morphology that will impact the parasite’s
future ability to infect and be transmitted.
It can be postulated that modulation of gGlcT1 and gFAELO causes global
changes in the encystation, infection, and transmission of Giardia (Figure 22). Future
work will focus on finding the precise catalytic regions of the enzyme as to investigate the
ultimate relevance of gGlcT1-related molecular changes on parasite infectivity and hostparasite interactions. Lipidomic analysis will also be performed to assess the global
changes in the lipid profiles to determine how the two enzymes are interacting at the
molecular level. This will confirm or deny that proper lipid homeostasis is important for
both encystation and excystation.
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Figure 22. The role of gGlcT1 and gFAELO in the encystation and excystation processes.
gGlcT1 is known to be induced upon encystation, but without the CGlcT1 or CGalT domains,
the cysts are smaller with thinner cyst walls most likely resulting in permeable cysts unable to
withstand environmental conditions. gFAELO is also induced upon encystation and persists
through the cyst. Due to its role in global lipid remodeling and a thinner cyst wall, it is predicted
to have a role in facilitating the excystation process where the cyst plasma membrane is
reorganized to become the plasma membrane of the two trophozoites that emerge and colonize
a host’s small intestine.
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